Supplementary Figure 5: Combined STAT5 activation and IKZF1 deletion status correlate best with survival and remission duration in patients with B-NOS progenitor B-ALL
From: Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival
(a) Survival of B-NOS B-ALL patients stratified by pSTAT5 and IKZF1 status. (b) Overall survival of B-NOS B-ALL patients that were stratified based on IKZF1 status alone (Δ = deletion). (c) Overall survival of B-NOS B-ALL patients that were separated into two equal-sized groups based on low or high pSTAT5 levels. (d,e) Overall survival of B-NOS B-ALL patients that were stratified by separating them based on IKZF1 status (WT or deleted) and then further subdividing those groups based pSTAT5 levels (low or high). (f) Remission duration in B-NOS B-ALL patients stratified by pSTAT5 and IKZF1 status. (g) Remission duration of B-NOS B-ALL patients that were stratified based on IKZF1 status alone (Δ = deletion). (h) Remission duration of B-NOS B-ALL patients that were separated into two equal-sized groups based on low or high pSTAT5 levels. (I,j) Remission duration of B-NOS B-ALL patients that were stratified by first separating them based on IKZF1 status (WT or deleted) and then further subdividing those groups based pSTAT5 levels (low or high). (k) Statistical summary of the results shown in panels (b-e) and (g-j). N.D. = not done. P-values determined by log-rank test for trends (a, f) or log-rank Mantle-Cox test (b,c,d,e,g,h,i,j).
